

Tim Muller - - tm@scientex.eu - <http://www.scientex.eu>

50 years , married, 3 children, French native, Tel: +33. 645.523. 540

Home & Office : Villa GOADIK 49 avenue du littoral 44380 Pornichet - FRANCE

Join our +55 000 contacts & followers on LINKEDIN

<https://www.linkedin.com/in/timotheemuller/>



SNAPSHOT :

Supporting CFO + CBO functions for healthcare SMEs : *Financing + IPO + Investor Relations + M&A + R&D partnering + Business Development & Licensing + corporate strategy & communications*

Education level : PhD in pharmaceutical sciences + MS in finance + MS in general management

Track record : IPO CROSSJECT after restart as CBO & board member + 26 board member positions since 1999 + 17 healthcare private equity investments + best venture exits and returns for Orphan Pharma International and Metabolic Explorer and involved in +100 various deals on both sell and buy side

10 years as private equity investor & 10 years as business developer both in healthcare :

After a first R&D experience on radiopharmaceuticals at AREVA R&D (CEA/IPSN) in 1993, Tim worked as a R&D pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabetes mellitus & CNS. In 1999, Tim joined the private equity industry (CDC enterprises now BPI & Sofimac Partners) investing in 17 healthcare companies (8 were acquired by industrials & 5 IPOs) from his 600 deal flow proactively sourced & screened. In 2006, Tim founded SCIENTEX, a healthcare dedicated advisory & transition management firm focused on business & corporate development, M&A (buy & sell side), while he was advising wealthy individuals on VIX trading & working with primary & secondary private equity funds. Since 2008, Tim led the business development activities of several biotech & pharma as head of M&A for Pharma Omnium, VP Bus Dev of Cytune Pharma & of Tetrahedron and head of BD for the CRO Kymos.... Tim joined CROSSJECT in 2012 during its restart in order to transform its ZENEO based medtech business model presenting a 2M€ valuation into an Euronext listed specialty pharma (IPO in feb 14 valued 65M€). After the successful completion of a 472M\$ ww R&D partnering deal on ZENEO epinephrin; Tim, acting as CBO & member of the executive board, led & drove the \$6M refinancing closed in june 2013 while managing M&A opportunities. Tim initiated & engaged the IPO process, successfully oversubscribed 4,4 x in feb 2014 through an european roadshow with the CEO & negotiated 2 out-licensing deals for ZENEO MTX covering China valued 360M€ including 25% royalties & covering Indian regions including royalties between 20% to 40%. For CROSSJECT, Tim was fully dedicated, full time, home based & commuting with 40% of ww travel and negotiated 8 term sheets. During 2016, Tim performed +300 commercial meetings on a ww basis and met 250 investors. Complementary, thanks to its broad healthcare database, SCIENTEX was also mandated to screen the 907 injectable drugs in order to double CROSSJECT's R&D portfolio : 200 injectables were ZENEO compatibles and 5 products have been selected and highlighted by SCIENTEX supporting the 6,7M euros grant from BPI/PIAVE. Globally, Tim has been involved in +100 corporate & business transactions, on sell & buy side, including 5 IPOs, 9 M&A, 8 out-licensing deals, 29 commercial deals, 28 financing deals with a worldwide coverage. Tim was board member for 26 companies and realized through SCIENTEX +30 missions in 10 years generating +2,5M€ of net fees

<http://www.scientex.eu/app/download/8649510/Tim+Muller++Scientex+full+package.pdf>

PROFESSIONAL EXPERIENCE

06/2012 – 03/2018 **CROSSJECT:** *self injectable pharmaceuticals* DIJON
Chief Business Officer & Executive Board Member through a mandate with Scientex

11/2013 – 02/2018 **KYMOS :** *analytical & clinical CRO* BARCELONA
Head of business development (FR, LUX, BEL, CH) through a mandate with Scientex

09/2011 – 03/2013 **TETRAHEDRON :** *healthcare nutrition & cosmetics CRO* PARIS
Vice President corporate & business development through a mandate with Scientex

- 2010 7 months** **CYTUNE PHARMA : biotech** NANTES
Vice President corporate & business development through a mandate with Scientex
- 07/2008 – 05/2012** **PHARMA OMNIUM INTERNATIONAL : biopharma** PARIS
Director commercial & partnership development (M&A) through a mandate with Scientex
- 02/2008 – 05/2010** **GO CAPITAL : private equity** RENNES
Venture Partner life sciences through a mandate with Scientex
- 09/2006 – 11/2008** **SCOTTISH ENTERPRISES: investment governmental body** GLASGOW
Senior Business Developer, healthcare & finance, EMEA through a mandate with Scientex
- 05/2006 - date** **SCIENTEX : advisory & transition management** PORNICHET
Founding CEO / healthcare focused corporate & business development firm
- M&A MISSIONS : BIOFORTIS, NICOX
 - MARKETING and SALES DEVELOPMENT MISSIONS : ELICITYL, DISCOVERX Corp,
 - STRATEGIC AUDIT : PHERECYDES Pharma, HEMARINA, METAFORA BIOS, MUTABILIS, MEDESIS Pharma, SATT Grand Ouest/NEUROCORT and COLT
 - R&D MISSIONS : CROSSJECT
 - FUNDRAISING MISSIONS : CROSSJECT, ELICITYL, NAOGEN PHARMA
 - PRIVATE EQUITY ADVISOR : ARCIS, DAHLIA Partners, Normandie Part, VFCFAR
 - SEED ENTREPRENEUR : MYELOMAX, INSERM, ATLANPOLE
- 03/2004 - 09/2006** **CDC ENTREPRISES (= BPI FRANCE) : private equity** PARIS
Partner healthcare / Venture & growth capital
- 03/1999 – 03/2004** **SOFIMAC PARTNERS : private equity** CLERMONT-FERRAND
General Partner life sciences / venture & growth capital & small LBO
- 09/1993 – 08/1998** **LABORATOIRES SERVIER : pharmaceuticals** COURBEVOIE
Senior research scientist on diabete mellitus and CNS
- 1993 8 months** **AREVA/CEA : radiopharmaceuticals** SACLAY
Project Engineer developing an analytical method for radioactive uranium complex

MAIN LAST ACHIEVEMENTS

- 17 early stage direct venture healthcare investments acting lead & co lead VC : only 2 companies failed, 5 IPOs, 8 M&As, 2 VC awards as best venture exit and best returns for Orphan Pharma International and Metabolic Explorer
- 19 MONTHS for restarting CROSSJECT in 2012 from a 9 people medtech start-up into a listed specialty pharma (70 FTE in 2018) : drove restart (\$6M private equity refinancing in may 2013, €17M IPO in feb 2014, IR as executive board member) in parallel with heading busdev & licensing as CBO (negotiated 8 licensing detailed term sheet and closed a \$ 470M partnering ww deal and a € 360M Chinese licensing deal and an indian licensing deal with royalties between 20% to 40%).
- Generate 2,5M€ of net consultancy fees for SCIENTEX from 2006 to 2018 acting as CFO/CBO for biotech start-up and venture partner for private equity funds.
- Build a huge network inside European private equity & family offices, worldwide biotech & pharmaceutical dealmakers.
- Structure a complete healthcare database of +20Go sourced from main healthcare intelligence providers & investment banks (deals, pipeline, market sizing & trends, forecast, epidemiology...).
- Screened + 572 biotech for Pharma Omnium International for M&A purpose, 2 acquisitions realized, negotiated a ww licensing deal between ADISSEO and TETRAHEDRON on healthcare nutrition market, generated +500K€ of quotation for the Spanish CRO KYMOS in year 1, doubled sales for Elicityl in year 1.
- 10 AWARDS received between 2016 to 2019 including BEST BUSINESS DEVELOPMENT COMPANY IN EUROPE by Acquisition International, the voice of corporate finance.

26 BOARD MEMBER POSITIONS since 1999

- Avidis SA (Vice President, 1999-2004, seed the spin off from MRC labs in Cambridge, now Imaxio 1999-

2004 and sold to the family office Edulis),

- Bionisis SA (Vice President, 99- 04),
- Cellpep SA (Vice President, 99-04, now AMBRILIA, listed on Toronto Stock Exchange through a RTO),
- Trophos SA (1999-2004, sold to Roche 470Meuros),
- OPI SA (99-04, sold to EUSA PHARMA 107Meuros, best venture exit in 2010),
- Txcell SA (2004-2006, co-lead the 10M€ serie A, 2004-2006 listed on Euronext, acquired by SANGAMO),
- Metabolic Explorer SA (listed, best venture exit price in 2008),
- Crossject SA (april 2013-to march 2017, listed on Euronext),
- Integragen SA (co-lead the pre-IPO serie D, listed on Euronext),
- Bioaccess SA, (sold to Biorad, IRR 3x the investment),
- Genolife SA (sold to Cambrex),
- Proteus SA (99-2004, sold to PCAS),
- Scynexis Inc (USA, now Listed on Nasdaq),
- Cyclopharma SA (acquired by Curium & Denos),
- Digestar SA, failed, • Nucleica SA (99-04), (bankrupt), • Entomed SA (2005-2006), • Biomethodes SA (2005-2006), • Scientex SARL (2006 to date), • Scimul SCI (2010 to date), • Ocean5 SCI (since 2018),
- Saphir GmbH (Germany), • PIL SA, • BMD SA, • LMD SA (bankrupt), • Synt:em SA (bankrupt) , • Greentech SA.

MAIN HOBBIES & DRIVERS

Sports addict : 5 to 7h per week, watersports and running, 182cm, 73kg

Results & value added, pragmatism, dynamic and hard worker, flexible, reliable, straightforward.